美股异动丨百济神州盘前涨4.5%，机构看好其迈入多曲线增长新纪元

格隆汇07-06

百济神州(ONC.US)盘前涨4.5%，报311美元。消息面上，百济神州依据MANGROVE研究取得的积极成果，打算于2026年下半年向全球监管机构提交泽布替尼联合利妥昔单抗用于一线套细胞淋巴瘤(MCL)治疗的上市申请。华福证券研报指出，百济神州效率驱动的全球化创新，迈入多曲线增长新纪元。公司血液肿瘤“三驾马车”已全面成型。泽布替尼2026将成为销售额最高的BTK抑制剂。索托克拉2026年美国与欧盟获批在即，固定疗程方案有望成为新一代标杆。BGB-16673预计2027年获批，三者协同覆盖CLL/SLL全线治疗，CLL治疗方案扩展与分子迭代计划明确，将彻底重塑治疗格局。(格隆汇)

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2649644763?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-06 16:16","share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","id":"2649644763","market":"us","top_or_hot":-1,"title":"美股异动丨百济神州盘前涨4.5%，机构看好其迈入多曲线增长新纪元","media":"格隆汇","content":"<html><body><p>百济神州(ONC.US)盘前涨4.5%，报311美元。消息面上，百济神州依据MANGROVE研究取得的积极成果，打算于2026年下半年向全球监管机构提交泽布替尼联合利妥昔单抗用于一线套细胞淋巴瘤(MCL)治疗的上市申请。华福证券研报指出，百济神州效率驱动的全球化创新，迈入多曲线增长新纪元。公司血液肿瘤“三驾马车”已全面成型。泽布替尼2026将成为销售额最高的BTK抑制剂。索托克拉2026年美国与欧盟获批在即，固定疗程方案有望成为新一代标杆。BGB-16673预计2027年获批，三者协同覆盖CLL/SLL全线治疗，CLL治疗方案扩展与分子迭代计划明确，将彻底重塑治疗格局。(格隆汇)</p></body></html>","source":"live_gelonghui","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美股异动丨百济神州盘前涨4.5%，机构看好其迈入多曲线增长新纪元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美股异动丨百济神州盘前涨4.5%，机构看好其迈入多曲线增长新纪元\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><p>百济神州(ONC.US)盘前涨4.5%，报311美元。消息面上，百济神州依据MANGROVE研究取得的积极成果，打算于2026年下半年向全球监管机构提交泽布替尼联合利妥昔单抗用于一线套细胞淋巴瘤(MCL)治疗的上市申请。华福证券研报指出，百济神州效率驱动的全球化创新，迈入多曲线增长新纪元。公司血液肿瘤“三驾马车”已全面成型。泽布替尼2026将成为销售额最高的BTK抑制剂。索托克拉2026年美国与欧盟获批在即，固定疗程方案有望成为新一代标杆。BGB-16673预计2027年获批，三者协同覆盖CLL/SLL全线治疗，CLL治疗方案扩展与分子迭代计划明确，将彻底重塑治疗格局。(格隆汇)</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.gelonghui.com/rss/live/live.xml\">格隆汇</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4526","symbol_name":"热门中概股","start_time":0,"source_url":"https://www.gelonghui.com/rss/live/live.xml","article_id":"2649644763","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649644763","pubTimestamp":1783325768,"columns":[],"sourceInfo":{"source_id":"live_gelonghui","name":"格隆汇"},"weMediaInfo":null,"summary":"百济神州(ONC.US)盘前涨4.5%，报311美元。消息面上，百济神州依据MANGROVE研究取得的积极成果，打算于2026年下半年向全球监管机构提交泽布替尼联合利妥昔单抗用于一线套细胞淋巴瘤(MC","collect":0,"end_time":0,"defaultTopTitle":"gelonghui.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4526":"热门中概股","ONC":"百济神州","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4139":"生物科技"},"translate_title":"BeiGene rose 4.5% before the market, and institutions are optimistic that it will enter a new era of multi-curve growth","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONC":1.5},"content_text":"百济神州(ONC.US)盘前涨4.5%，报311美元。消息面上，百济神州依据MANGROVE研究取得的积极成果，打算于2026年下半年向全球监管机构提交泽布替尼联合利妥昔单抗用于一线套细胞淋巴瘤(MCL)治疗的上市申请。华福证券研报指出，百济神州效率驱动的全球化创新，迈入多曲线增长新纪元。公司血液肿瘤“三驾马车”已全面成型。泽布替尼2026将成为销售额最高的BTK抑制剂。索托克拉2026年美国与欧盟获批在即，固定疗程方案有望成为新一代标杆。BGB-16673预计2027年获批，三者协同覆盖CLL/SLL全线治疗，CLL治疗方案扩展与分子迭代计划明确，将彻底重塑治疗格局。(格隆汇)","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649644763","isCrawlerRequest":true}